DNA Sciences Soars 10.12% After Reverse Split and Q2 Earnings Beat

DNA Sciences rose 10.12% in pre-market trading on June 3, 2025.

Applied DNA Sciences announced a 1-for-15 reverse stock split effective June 2, 2025, to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The reverse split reduced outstanding shares from approximately 7.8 million to 519 thousand, maintaining trading under the symbol "APDN."

The company also rescheduled its intra-quarter webcast and investor update call to June 17, 2025, due to the implementation of the reverse stock split. The webcast will include prepared remarks from management and a Q&A session with analysts and investors.

Applied DNA Sciences reported second quarter fiscal 2025 financial results, showing total revenues of $983K, a 6% increase year-over-year. The LineaRx segment saw a 44% revenue increase, while MDx Testing Services revenue declined 33%. The company reported a net loss of $3.3M, an improvement from the $4.5M loss in the previous year.